Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary

Siqi Wen1,2,3, Chunling Li4, Xianquan Zhan1,2,5

  • 1Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, 440 Jiyan Road, Jinan, Shandong 250117 People's Republic of China.

The EPMA Journal
|March 11, 2022
PubMed

Insights

Nonfunctional pituitary neuroendocrine tumors (NF-PitNETs) involve complex molecular networks. Understanding these altered signaling pathways offers new therapeutic targets for aggressive tumors.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Nonfunctional pituitary neuroendocrine tumors (NF-PitNETs) are common intracranial tumors with significant heterogeneity.
  • NF-PitNET pathogenesis involves alterations across genomic, transcriptomic, proteomic, and metabolomic levels, forming complex molecular networks.

Purpose of the Study:

  • To review signaling pathway alterations in NF-PitNETs using integrative omics data.
  • To emphasize pathways linked to NF-PitNET invasiveness and aggressiveness.
  • To summarize current and potential therapeutic agents targeting these pathways.

Main Methods:

  • Integrative omics analyses (genome, transcriptome, proteome, metabolome).
  • Review of literature on signaling pathway alterations in NF-PitNETs.
  • Focus on pathways including calcium, cGMP-PKG, mTOR, PI3K/AKT, and MAPK signaling.

Main Results:

  • Identified key signaling pathway networks crucial for NF-PitNET formation and progression.
  • Highlighted altered pathways and molecules associated with tumor invasiveness and aggressiveness.
  • Summarized targeted therapies and potential agents for NF-PitNET treatment.

Conclusions:

  • Signaling pathway network alterations are central to NF-PitNET development and progression.
  • Understanding these networks provides insights into molecular mechanisms and identifies therapeutic targets.
  • This knowledge aids in biomarker discovery, patient stratification, and targeted NF-PitNET therapy.